SCHEMBL15670299

SCHEMBL15670299

CCOC(=O)C(NC(=O)OC(C)(C)C)c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.46
CTSK P43235 1/20 0.46
RAB9A P51151 1/20 0.44
NAMPT P43490 2/20 0.43
GAA P10253 2/20 0.41
MAPK1 P28482 1/20 0.41
CYP3A4 P08684 7/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPT P10636 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
S1PR3 Q99500 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15270209 0.89 RAB9A (0.47) CTSSCTSKRAB9ANAMPTCYP3A4
SCHEMBL19318503 0.85 GAA (0.43) RAB9AGAAMAPK1CYP3A4SMN1; SMN2
SCHEMBL5814774 0.85 CTSS (0.47) CTSSCTSKNAMPTGAASMN1; SMN2
SCHEMBL4148003 0.85 CTSS (0.50) CTSSCTSKRAB9ANAMPTCYP3A4
SCHEMBL1480134 0.85 CTSS (0.50) CTSSCTSKRAB9ANAMPTCYP3A4
SCHEMBL4148011 0.85 CTSS (0.50) CTSSCTSKRAB9ANAMPTCYP3A4
SCHEMBL27833801 0.84 CTSK (0.62) CTSSCTSKSMN1; SMN2ALDH1A1MAPT
SCHEMBL10240502 0.84 CTSK (0.62) CTSSCTSKSMN1; SMN2ALDH1A1MAPT
SCHEMBL12294538 0.84 RAB9A (0.41) CTSSCTSKRAB9ANAMPTGAA
SCHEMBL19323039 0.83 POLB (0.51) RAB9AGAAMAPK1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2912034-B1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL HOFFMANN LA ROCHE (CH) 2017-05-31 EP disclosed
US-9611232-B2 Oxazolidinone and imidazolidinone compounds HOFFMANN-LA ROCHE INC. (US) 2017-04-04 US disclosed
US-20150246894-A1 NOVEL OXAZOLIDINONE COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-09-03 US disclosed
EP-2912034-A1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL F. Hoffmann-La Roche AG (CH) 2015-09-02 EP disclosed
WO-2014067861-A1 3,4-DISUBSTITUTED OXAZOLIDINONE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE CALCIUM ACTIVATED POTASSIUM CHANNEL F. HOFFMANN-LA ROCHE AG (CH) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246894-A1 NOVEL OXAZOLIDINONE COMPOUNDS OXA1L, CDK11B, CDK11A CTSS 4536/4885CTSK 3065/4885RAB9A 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.